$PTE News
Last published 2y ago
- 2y agoPTEMulti-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUs II) - NCT06140303ClinicalTrials.govIncidence of index ulcers closed, Percent area reduction (PAR), Total number of in person wound care clinic visits and/or hospital days related to the index ulcer., (and 2 more...)
- 3y agoPTEPolarityTE Announces Entry Into a Letter of Intent For Acquisition of the CompanyPR NewswireSALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a
- 4y agoPTEPolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the CompanyPR NewswireSALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an
- 4y agoPTEPolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022PR NewswireSALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the H.C. Wainwright 24th Annual Global Investment Conferenc
- 4y agoPTEPolarityTE Announces Resignation of Jeff Dyer from its Board of DirectorsPR NewswireSALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effectiv
- 4y agoPTEPolarityTE Reports Second Quarter 2022 Financial Results and Provides Business UpdatePR NewswirePolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today p
- 4y agoPTEPolarityTE to Report Q2 2022 Financial Results on August 11, 2022PR NewswireSALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.
- 4y agoPTEPolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq RulesPR NewswireSALT LAKE CITY, June 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single healthcare
- 4y agoPTEPolarityTE to Attend H.C. Wainwright Global Investment ConferencePR NewswireSALT LAKE CITY, May 23, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will present at the upcoming H.C. Wainwright Global Investment C
- 4y agoPTEPolarityTE to Effectuate 1-for-25 Reverse Stock SplitPR NewswireSALT LAKE CITY, May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will effectuate a 1-for-25 reverse stock split of the Company's
- 4y agoPTEPolarityTE Reports First Quarter 2022 Financial Results and Provides Business UpdatePR NewswirePolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET SALT LAKE CITY, May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today prov
- 4y agoPTEPolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®PR NewswireSALT LAKE CITY, May 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company's open IND.
- 4y agoPTEMulti-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs - NCT05372809ClinicalTrials.govIncidence of index ulcers closed, Percent area reduction (PAR), Wound Quality of Life (w-QoL) Questionnaire, Wound infection
- 4y agoPTEPolarityTE to Report Q1 2021 Financial Results on May 16, 2022PR NewswireSALT LAKE CITY, May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 16, 2022, at approximately 7:30 a.m. Eastern Time.
- 4y agoPTEPolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot UlcersPR NewswireSALT LAKE CITY, May 3, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers
- 4y agoAGRXBBBYPHIOPTE+1Thinking about buying stock in Agile Therapeutics, Polarityte, Bed Bath & Beyond, Tellurian, or Phio Pharmaceuticals?PR NewswireNEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, PTE, BBBY, TELL, and PHIO.
- 4y agoATERCYCCNILEPTE+1Thinking about buying stock in Polarityte, RLX Technology, Bitnile, Aterian, or Cyclacel Pharmaceuticals?PR NewswireNEW YORK, April 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, RLX, NILE, ATER, and CYCC. T
- 4y agoPTEPolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business UpdatePR NewswirePolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET SALT LAKE CITY, March 30, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today p
- 4y agoPTEPolarityTE Announces Closing of $5.0 Million Registered Direct OfferingPR NewswireSALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has closed its previously announced r
- 4y agoPTEPolarityTE Announces $5.0 Million Registered Direct OfferingPR NewswireSALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has entered into a securities purchas
- 4y agoPTEPolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022PR NewswireSALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2022, at approximately 7:30 a.m. Eastern Time.
- 4y agoPTESkinTE® Met Primary and Secondary Endpoints in Multicenter, Randomized Controlled Trial in Venous Leg UlcersPR NewswireSALT LAKE CITY, Feb. 22, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced results from a multi-center randomized controlled trial evaluating treatment of Venous Leg Ulcers (VLU) with its investigational product SkinTE® plus standard of
- 4y agoPTEPolarityTE Announces Allowance of Fourth U.S. PatentPR NewswireSALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowa
- 4y agoIONCMIOPKPLTK+1Thinking about buying stock in Polarityte, Opko Health, Ion Geophysical, National CineMedia, or Playtika?PR NewswireNEW YORK, Jan. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, OPK, IO, NCMI, and PLTK. To
- 4y agoPTEPolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer IndicationPR NewswireSALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investi
- 4y agoBLCTFRONINEPTE+1Thinking about buying stock in Siyata Mobile, Nine Energy Service, BlueCity, Polarityte, or Frontline?PR NewswireNEW YORK, Jan. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SYTA, NINE, BLCT, PTE, and FRO. To
- 4y agoPTEPolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug ApplicationPR NewswireSALT LAKE CITY, Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its complete response to the U.S. Food and Drug Administr
- 5y agoPTEPolarityTE Reports Third Quarter Financial Results and Provides Business UpdatePR NewswireSALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the three and nine-month pe
- 5y agoPTEPolarityTE to Report Third Quarter Financial Results on November 10, 2021PR NewswireSALT LAKE CITY, Oct. 28, 2021 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended September 30, 2021 by press release on Wednesday, November 10, 2021 at approximately 7:00 a.m. Eastern
- 5y agoPTEPolarityTE Provides Update on Investigational New Drug ApplicationPR NewswireSALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding its Investigational New Drug Application (IND) for SkinT
- 5y agoPTEPolarityTE to Attend H.C. Wainwright 23rd Annual Global Investment Conference and 2021 Cantor Virtual Global Healthcare ConferenceBusiness WirePolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021 and participate in
- 5y agoPTEPolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg to Board of Directors and Chair of Strategic Review CommitteeBusiness WireRyan Mathis, MD, named Chief Medical Officer PolarityTE, Inc. (NASDAQ:PTE) today announced the appointment of Richard Hague as Chief Executive Officer, the election of David Seaburg to the Board of Directors, and the appointment of Ryan Mathis, MD, a
- 5y agoPTEPolarityTE Reports Second Quarter Financial Results and Provides Business UpdateBusiness WirePolarityTE to host conference call and webcast today, August 12, 2021, at 4:30 p.m. ET PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported fina
- 5y agoPTEPolarityTE to Report Second Quarter Financial Results on August 12, 2021Business WirePolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2021 by press release on Thursday, August 12, 2021 at approximately 4:00 p.m. Eastern Time. In addition, the Company will host a conference call
- 5y agoPTESkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer TrialBusiness WireData Included in Investigational New Drug Application Submitted on July 23, 2021 Company Announces Completion of Study Evaluating SkinTE for the treatment of Venous Leg Ulcers PolarityTE, Inc. (NASDAQ:PTE) today announced final data from a multi-
- 5y agoPTEPolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous UlcersBusiness WirePolarityTE, Inc. (NASDAQ:PTE) today announced the submission of an investigational new drug application (IND) to the United States Food and Drug Administration (FDA) seeking authorization to commence a clinical trial to evaluate its SkinTE product for t
- 5y agoPTEPolarityTE Issues Statement About Potential Ticker Symbol ConfusionBusiness WirePolarityTE, Inc. (NASDAQ:PTE) is issuing the following statement: Based on investor inquiries, it has been brought to the attention of PolarityTE that there may be confusion amongst the investment community related to PolarityTE's stock and Peet DeFi
- 5y agoPTEPolarityTE Receives Notice of Allowance for Chinese PatentBusiness WirePolarityTE's Worldwide Patent Portfolio Grows to 12 Allowed or Granted Patents PolarityTE, Inc. (NASDAQ:PTE) today announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Ap
- 5y agoADAPONCTONCYPRPO+1Thinking about buying stock in Oncternal Therapeutics, Polarityte, Adaptimmune Therapeutics, Oncolytics Biotech, or Precipio?PR NewswireNEW YORK, May 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCT, PTE, ADAP, ONCY, and PRPO. To
- 5y agoPTEPolarityTE Reports First Quarter Results and Provides Business UpdateBusiness WireFirst Quarter 2021 Total Revenues of $4.71 million Compared to $3.59 million in Fourth Quarter of 2020 PolarityTE to host conference call and webcast today, May 13, 2021 at 4:30 p.m. ET PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company devel
- 5y agoPTEPolarityTE, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 13, 2021 / PolarityTE, Inc. (NASDAQ:PTE) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time. To listen to the event live or access a repl
- 5y agoALTAMCIHRTPTE+1Thinking about buying stock in Polarityte, AMC Entertainment, Altimmune, iHeartMedia, or Vale?PR NewswireNEW YORK, May 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, AMC, ALT, IHRT, and VALE. To se
- 5y agoPTEPolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary EndpointBusiness WireReports Peer-Reviewed Publication of Interim Results from Diabetic Foot Ulcer Trial in International Wound Journal PolarityTE, Inc. (NASDAQ:PTE) today announced preliminary topline data demonstrating that a multi-center randomized controlled trial ev
- 5y agoPTEPolarityTE to Report First Quarter Financial Results on May 13, 2021Business WirePolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended March 31, 2021 by press release on Thursday, May 13, 2021 at approximately 4:00 p.m. Eastern Time. In addition, the Company will host a conference call an
- 5y agoPTEPolarityTE Reports Fourth Quarter and Fiscal Year 2020 ResultsBusiness WireSALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the fourth quarter and fiscal year ended December 31, 2020.
- 5y agoPTEPolarityTE to Report Fiscal Year 2020 Financial Results on March 30, 2021Business WireSALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2020 by press release on Tuesday, March 30, 2021 at approximately 7:00 a.m. Eastern Time.
- 5y agoPTEPolarityTE to Present at the H.C. Wainwright Global Life Sciences Virtual ConferenceBusiness WireSALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright Global Life Sciences Virtual Conference held March 9-10, 2021.
- 5y agoPTEStella Diagnostics Announces Key Additions to its Board of DirectorsACCESS Newswire. (OTC PINK:JMDP) ("Stella" or "The Company") today announced that it has appointed Peter A. Cohen, Seth Platt, and David Seaburg to its Board of Directors. The three new members have decades of experience in asset management, investment banking and corporate development - having held various executive roles for multiple leading, global institutions.
- 5y agoVIEPTERVNCAmbrx Appoints Audit Executive Chris Nolet to Board of DirectorsBusiness WireSAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s ...
- 5y agoPTEPolarityTE Provides Corporate UpdateBusiness WireSALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide this update. Our focus is on building shareholder value by pursuing pre-market approval for SkinTE® from the U.S. Food and Drug Administration (FDA) through submission of an investigational new drug application ...